An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
CA 2379105 A1 · Owner: Astrazeneca Ab · Inventors: Abrahamsson, Bertil; Ungell, Anna-Lena; Lindqvist, Ann-Margret
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor compound) and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor compound in the ileum. The IBAT inhibitor compound can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compound such as for , instance diarrhoea. The bile acid binder may be formulated for colon release.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 19, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 19, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 19, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.